DRI19220 Enrolling

Hidradenitis Suppurativa Study (60 Weeks)


Treatment: subcutaneous Age: 18 Years and older


Who Can Participate?
Male or female aged 18 or above with hidradenitis suppurativa (HS) may participate.

Inclusion Criteria
• Diagnosis of moderate to severe HS for at least 6 months
• Must have HS lesions present in at least 2 distinct anatomic areas

Participant Information
• Participate and receive study treatment at no cost
• Regular visits with study doctors who specialise in treating hidradenitis suppurativa (28 visits)
• Will receive either an investigative subcutaneous (SC) injection treatment (study drug) or a placebo
• Reimbursement for study-related expenses may be provided

How Long Will The Study Last?
• 60 weeks


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: November 17, 2025

Official Title

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID

NCT07170917

Sponsor

Sanofi

Study Description

  • Brief Summary:

    This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of this study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study. The randomized treatment duration will be up to approximately 48 weeks.

  • Condition or Disease:

    Hidradenitis Suppurativa

  • Intervention/Treatment:

    Drug: Brivekimig Drug: Brivekimig Drug: Brivekimig Drug: Placebo
  • Phase:

    PHASE2

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Hidradenitis Suppurativa

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content